Xiaoming Shu

2.1k total citations
76 papers, 1.6k citations indexed

About

Xiaoming Shu is a scholar working on Epidemiology, Rheumatology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Xiaoming Shu has authored 76 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 47 papers in Epidemiology, 36 papers in Rheumatology and 17 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Xiaoming Shu's work include Inflammatory Myopathies and Dermatomyositis (45 papers), Eosinophilic Disorders and Syndromes (27 papers) and Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (13 papers). Xiaoming Shu is often cited by papers focused on Inflammatory Myopathies and Dermatomyositis (45 papers), Eosinophilic Disorders and Syndromes (27 papers) and Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (13 papers). Xiaoming Shu collaborates with scholars based in China, Canada and United States. Xiaoming Shu's co-authors include Guochun Wang, Qinglin Peng, Xin Lu, Sigong Zhang, Hanbo Yang, Xin Lü, Guochun Wang, Yongpeng Ge, Xiaolan Tian and Shanshan Li and has published in prestigious journals such as PLoS ONE, Scientific Reports and Frontiers in Immunology.

In The Last Decade

Xiaoming Shu

74 papers receiving 1.5k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Xiaoming Shu China 21 942 684 395 379 275 76 1.6k
Qinlong Zheng Denmark 23 296 0.3× 391 0.6× 204 0.5× 457 1.2× 209 0.8× 46 1.6k
L. Astudillo France 17 282 0.3× 203 0.3× 89 0.2× 342 0.9× 162 0.6× 69 1.2k
Silvia Svegliati Italy 25 279 0.3× 307 0.4× 623 1.6× 606 1.6× 405 1.5× 43 2.1k
Alessandra Nerviani United Kingdom 24 111 0.1× 674 1.0× 925 2.3× 495 1.3× 83 0.3× 49 1.8k
Ryosuke Saigusa Japan 20 292 0.3× 169 0.2× 764 1.9× 439 1.2× 232 0.8× 59 1.5k
Christina Bergmann Germany 18 225 0.2× 165 0.2× 331 0.8× 808 2.1× 424 1.5× 53 1.9k
Dirk Pohlers Germany 17 103 0.1× 423 0.6× 211 0.5× 552 1.5× 119 0.4× 26 1.4k
Robert I. Parker United States 16 478 0.5× 171 0.3× 171 0.4× 375 1.0× 62 0.2× 42 1.6k
Chin‐Jung Hsu Taiwan 28 317 0.3× 348 0.5× 317 0.8× 720 1.9× 102 0.4× 62 1.8k
Nicola Maruotti Italy 23 100 0.1× 440 0.6× 259 0.7× 615 1.6× 83 0.3× 54 1.6k

Countries citing papers authored by Xiaoming Shu

Since Specialization
Citations

This map shows the geographic impact of Xiaoming Shu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xiaoming Shu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xiaoming Shu more than expected).

Fields of papers citing papers by Xiaoming Shu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xiaoming Shu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xiaoming Shu. The network helps show where Xiaoming Shu may publish in the future.

Co-authorship network of co-authors of Xiaoming Shu

This figure shows the co-authorship network connecting the top 25 collaborators of Xiaoming Shu. A scholar is included among the top collaborators of Xiaoming Shu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xiaoming Shu. Xiaoming Shu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Shu, Xiaoming, et al.. (2024). Effectiveness and safety of eltrombopag in connective tissue disease patients with refractory immune thrombocytopenia: a retrospective study. Rheumatology Advances in Practice. 8(2). rkae029–rkae029. 1 indexed citations
2.
Liu, Lei, Xinwang Duan, Lili Jiang, et al.. (2024). Longitudinal study of patients with anti-SAE antibody-positive dermatomyositis: a multicenter cohort study in China. Lara D. Veeken. 64(3). 1377–1385. 2 indexed citations
3.
4.
He, Linrong, Yongpeng Ge, & Xiaoming Shu. (2024). Fever, low back pain and skin ulcerations. Annals of the Rheumatic Diseases. 83(10). 1389–1389. 1 indexed citations
5.
Zhang, Yinli, Zhengyi Cao, Xiaoming Shu, et al.. (2023). Decrease in cell counts and alteration of phenotype characterize peripheral NK cells of patients with anti-MDA5-positive dermatomyositis. Clinica Chimica Acta. 543. 117321–117321. 11 indexed citations
6.
Liu, Lijun, Yinli Zhang, Shengyun Liu, et al.. (2023). Compounded sulfamethoxazole improved the prognosis of dermatomyositis patients positive with anti-melanoma differentiation-associated gene 5. Lara D. Veeken. 62(9). 3095–3100. 8 indexed citations
7.
Fu, Lijun, Hongxia Yang, Zhenguo Huang, et al.. (2023). Peripheral lymphocyte count defines the clinical phenotypes and prognosis in patients with anti‐MDA5‐positive dermatomyositis. Journal of Internal Medicine. 293(4). 494–507. 34 indexed citations
8.
9.
Shu, Xiaoming, Dan Cao, Li Zheng, et al.. (2019). PEG-derivatized birinapant as a nanomicellar carrier of paclitaxel delivery for cancer therapy. Colloids and Surfaces B Biointerfaces. 182. 110356–110356. 10 indexed citations
10.
Shu, Xiaoming, et al.. (2018). New Co(II) And Mn(II) Complexes with 4′-Substituted 2,2′:6′,2″-Terpyridine Ligands. Journal of Structural Chemistry. 59(2). 398–410. 6 indexed citations
11.
Zhang, Yamei, Hanbo Yang, Jingli Shi, et al.. (2018). The prevalence and clinical significance of anti-PUF60 antibodies in patients with idiopathic inflammatory myopathy. Clinical Rheumatology. 37(6). 1573–1580. 12 indexed citations
12.
Ge, Yongpeng, Xin Lu, Xiaoming Shu, Qinglin Peng, & Guochun Wang. (2017). Clinical characteristics of anti-SAE antibodies in Chinese patients with dermatomyositis in comparison with different patient cohorts. Scientific Reports. 7(1). 188–188. 67 indexed citations
13.
Shu, Xiaoming, Xiaoxiang Xu, Qinglin Peng, et al.. (2017). Diagnostic value of PET/CT for giant cell arteritis combined with pulmonary embolism presenting. Medicine. 96(31). e7651–e7651. 2 indexed citations
14.
Yang, Hanbo, Qinglin Peng, Shanshan Li, et al.. (2017). Identification of multiple cancer-associated myositis-specific autoantibodies in idiopathic inflammatory myopathies: a large longitudinal cohort study. Arthritis Research & Therapy. 19(1). 259–259. 123 indexed citations
15.
Lu, Dan, Li Zhu, Xiaoming Shu, et al.. (2015). Ginsenoside Rg1 relievestert-Butyl hydroperoxide-induced cell impairment in mouse microglial BV2 cells. Journal of Asian Natural Products Research. 17(9). 930–945. 14 indexed citations
16.
Peng, Qinglin, Yinli Zhang, Xiaoming Shu, et al.. (2015). Elevated Serum Levels of Soluble CD163 in Polymyositis and Dermatomyositis: Associated with Macrophage Infiltration in Muscle Tissue. The Journal of Rheumatology. 42(6). 979–987. 36 indexed citations
17.
Zhu, Li, Wei Bi, Dan Lu, et al.. (2014). Regulation of ubiquitin-specific processing protease 8 suppresses neuroinflammation. Molecular and Cellular Neuroscience. 64. 74–83. 16 indexed citations
18.
Peng, Qinglin, et al.. (2012). [The levels and clinical significance of serum B cell activating factor in Chinese patients with polymyositis or dermatomyositis].. PubMed. 51(3). 210–3. 3 indexed citations
19.
Chen, Fang, Dongxue Wang, Xiaoming Shu, Ran Nakashima, & Guochun Wang. (2011). Anti-MDA5 antibody is associated with A/SIP and decreased T cells in peripheral blood and predicts poor prognosis of ILD in Chinese patients with dermatomyositis. Rheumatology International. 32(12). 3909–3915. 91 indexed citations
20.
Shu, Xiaoming, Guochun Wang, Xin Lü, & Yao Xie. (2009). Rheumatoid-like deformities in Parkinson’s disease with 1-year follow-up: case report and literature review. Rheumatology International. 30(11). 1493–1497. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Qinlong Zheng Breakdown of academic impact, for papers by L. Astudillo Breakdown of academic impact, for papers by Silvia Svegliati Breakdown of academic impact, for papers by Alessandra Nerviani Breakdown of academic impact, for papers by Ryosuke Saigusa Breakdown of academic impact, for papers by Christina Bergmann Breakdown of academic impact, for papers by Dirk Pohlers Breakdown of academic impact, for papers by Robert I. Parker Breakdown of academic impact, for papers by Chin‐Jung Hsu Breakdown of academic impact, for papers by Nicola Maruotti
Rankless by CCL
2026